11/19
10:51 am
ctmx
Down -25.59% in 4 Weeks, Here's Why CytomX Therapeutics (CTMX) Looks Ripe for a Turnaround [Yahoo! Finance]
Low
Report
Down -25.59% in 4 Weeks, Here's Why CytomX Therapeutics (CTMX) Looks Ripe for a Turnaround [Yahoo! Finance]
11/11
10:22 am
ctmx
CytomX Therapeutics, Inc. (NASDAQ: CTMX) had its "neutral" rating re-affirmed by analysts at HC Wainwright.
Medium
Report
CytomX Therapeutics, Inc. (NASDAQ: CTMX) had its "neutral" rating re-affirmed by analysts at HC Wainwright.
11/8
02:48 am
ctmx
CytomX Therapeutics Inc (CTMX) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid ... [Yahoo! Finance]
Low
Report
CytomX Therapeutics Inc (CTMX) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid ... [Yahoo! Finance]
11/7
07:48 pm
ctmx
CytomX Therapeutics (CTMX) Q3 Earnings and Revenues Top Estimates [Yahoo! Finance]
Low
Report
CytomX Therapeutics (CTMX) Q3 Earnings and Revenues Top Estimates [Yahoo! Finance]
11/7
04:23 pm
ctmx
CytomX Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update [Yahoo! Finance]
Medium
Report
CytomX Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update [Yahoo! Finance]
11/7
04:10 pm
ctmx
CytomX Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
Medium
Report
CytomX Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
11/6
07:57 am
ctmx
Earnings To Watch: CytomX Therapeutics Inc (CTMX) Reports Q3 2024 Result [Yahoo! Finance]
Low
Report
Earnings To Watch: CytomX Therapeutics Inc (CTMX) Reports Q3 2024 Result [Yahoo! Finance]
10/31
08:00 am
ctmx
CytomX Therapeutics to Report Third Quarter 2024 Financial Results on November 7, 2024
Low
Report
CytomX Therapeutics to Report Third Quarter 2024 Financial Results on November 7, 2024
9/13
08:02 am
ctmx
CytomX Therapeutics, Inc. (NASDAQ: CTMX) had its "neutral" rating re-affirmed by analysts at HC Wainwright.
Medium
Report
CytomX Therapeutics, Inc. (NASDAQ: CTMX) had its "neutral" rating re-affirmed by analysts at HC Wainwright.
9/9
08:00 am
ctmx
CytomX Therapeutics Announces First Patient Dosed with CX-801, a Dually-Masked Interferon-Alpha 2b PROBODY®, in a Phase 1 Study in Patients with Solid Tumors
Medium
Report
CytomX Therapeutics Announces First Patient Dosed with CX-801, a Dually-Masked Interferon-Alpha 2b PROBODY®, in a Phase 1 Study in Patients with Solid Tumors
9/4
08:00 am
ctmx
CytomX Therapeutics to Present at Upcoming September Investor Conferences
High
Report
CytomX Therapeutics to Present at Upcoming September Investor Conferences